●ASX-READY • COMMERCIAL STAGE • EST. 2001

Precision diagnostics
for the cancers that
still slip through.

Minomic is an Australian molecular diagnostics company
commercialising a blood-based biomarker platform for solid tumours –
starting with prostate, and extending to bladder and pancreatic
cancer. MiCheck® Prostate is reimbursed and shipping today in the US
and Australia.

US Medicare

Reimbursed

PLA code assigned, 2025

Markets live

US + AU

UK/EU signed for 2026

IP portfoli0

40+ assets

Solid-tumour biomarkers

Addressable men

≈ 1M / yr

Elevated-PSA biopsy decisions

Regulated · Reimbursed · In-market with

US CLIA-certified lab      Medicare registered      Sonic DHM (AU)      20/20 GeneSystems (US)      Doc Lab Inc.      Macquarie University Hospital

●THE PLATFORM • MiCheck®

A biomarker panel for the moment a urologist must decide.

MiCheck® Prostate is for male patients being considered for a prostate biopsy. It supplements – not replaces – the clinical judgement of the urologist, delivering a clinically significant prostate cancer risk score from a single blood draw.

MiCheck® Prostate · Patient Report

ID · MC-24-00412

Clinically significant prostate cancer — risk score

72 /100
Low Intermediate Elevated

Recommendation

Consider
biopsy referral

✓ Ease of use

Blood collection made at the same time as the PSA draw — no new workflow.

✓ Clear clinical utility

Single-page, well-defined report that supports the biopsy decision.

✓ Timely delivery

Results ready for the patient's next visit to the clinician.

✓ Dominant health economics

Favourable versus standard of care across payer models.

●THE OPPORTUNITY

A biomarker panel for the moment a urologist must decide.

Prostate biopsy decisions rely on PSA – a test known to over-refer. Precision-diagnostic peers built multi-billion-dollar businesses on solving similar decision points in other tumours. MiCheck® targets the same unmet need in the world’s most-diagnosed male cancer.

US prostate biopsies annually

1.2M+

The majority of which are ultimately negative for clinically significant disease.

Global molecular diagnostics market

$14B

Growing at a double-digit CAGR through the decade.

New US prostate cancer cases (2024)

268K

The most-diagnosed cancer in men – and rising.

●PIPELINE

One platform. A portfolio of solid-tumour programs.

A comprehensive intellectual property portfolio spanning prostate, bladder and pancreatic cancer – each targeting a decision-point with unmet need.

Indication

Asset

Stage

Status

Prostate

MiCheck® Prostate

Disc Anal Clin Regu Comm

Commercial · US + AU

Bladder

MiCheck® Bladder

Disc Anal Clin Regu Comm

Clinical validation

Pancreatic

MiCheck® Pancreatic

Disc Anal Clin Regu Comm

Biomarker discovery

●EXECUTION HISTORY

Six years of regulated, commercial-grade milestones.

2026

Execution of UK & European MiCheck® Prostate distribution agreement.

2025

MiCheck® Prostate receives PLA Code assignment.
Strategic partnership with Doc Lab Inc.
Completion of the MRI study in Australia.

2024

Minomic Inc. launches direct-to-consumer marketing platform with RoseRx.

2023

US reimbursement confirmed.
MiCheck® Prostate available through Douglass Hanly Moir laboratories in Australia.

2022

US — Medicare Registration received.
US — First commercial samples processed.
AU — Clinical validation completed at Macquarie University Hospital.

2021

Commercial partnership with 20/20 GeneSystems for the US market.
MiCheck® Prostate LDT roll-out.

●Expert opinion · ASCO GU 2022

“There is a clear, unmet need for a more accurate test to identify the patients who genuinely require a prostate biopsy — and a biomarker panel to support imaging.”

NS

Neal D. Shore, MD, FACS · Prof. Mark Emberton OBE

ASCO Genitourinary Cancers Symposium · University College London

●NEWSROOM

Discover our progress.

Regulatory

2025

MiCheck® Prostate receives PLA code assignment

Read →

Partnership

2025

Strategic partnership signed with Doc Lab Inc.

Read →

Clinical

2025

Australian MRI study completed

Read →

For Investors

A commercial
diagnostics
business with a
platform runway.

Request the current investor brief, upcoming milestone calendar
and detailed pipeline dossier.

Request investor brief →